Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
- Details
- Category: Small Molecules
- Published on Tuesday, 27 June 2023 11:04
- Hits: 2085
TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model
Company to participate in upcoming Piper Sandler Inaugural Obesity Investor Day on June 28th
Company to host webinar detailing Terns’ Obesity Franchise on June 29th at 11:00 a.m. ET
FOSTER CITY, CA, USA I June 26, 2023 I Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company’s novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego.
“We are excited by these new preclinical data shared at ADA, which demonstrate the ability of TERN-601 to significantly improve glucose tolerance, suppress food intake and slow gastric emptying in transgenic mice,” said Sen Sundaram, chief executive officer at Terns. “These data are very encouraging and support our plans to initiate a Phase 1 first-in-human clinical trial in subjects with an elevated body mass index in the second half of this year, with top-line data expected in 2024.”
Humanized GLP-1R (hGLP-1R) mice were used to assess the in vivo pharmacodynamics of TERN-601. In an intraperitoneal glucose tolerance test, all TERN-601 doses reduced blood glucose in hGLP-1R mice during glucose challenge. Food intake was also recorded for 24 hours in fasted mice treated with TERN-601, with food available 15 minutes post dose. TERN-601 reduced food-intake in fasted hGLPR-1R mice. Acetaminophen (APAP) plasma levels were reduced in fasted hGLP-1R mice administered TERN-601 four hours prior to oral ingestion of APAP-glucose solution, indicating slowed gastric emptying. The full poster is available on Terns’ scientific publications website.
In addition, Terns announces that management will participate in a Fireside Chat at the Piper Sandler Inaugural Obesity Investor Day and will host a webinar to review Terns’ obesity franchise, including the TERN-601 program and additional development efforts underway in obesity.
Piper Sandler Inaugural Obesity Investor Day:
Date and Time: June 28, 2023 at 11:30 a.m. ET
The Piper Sandler event webcast link is available from Piper Sandler and will require registration.
Terns Obesity Franchise Webinar:
Date and Time: June 29, 2023 at 11:00 a.m. ET
Webinar Link: Register
A webcast of Terns’ obesity event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns’ pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/- an FXR agonist), and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.
SOURCE: Terns Pharmaceuticals